CARsgen Therapeutics Holdings Ltd. (2171) Price & Analysis

CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 15, 2025. The company reported -HK$0.153 earnings per share for the quarter, beating the consensus estimate of -HK$0.437 by HK$0.284.

Is CARsgen Therapeutics Holdings Ltd. overvalued?

According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CARsgen Therapeutics Holdings Ltd. pay dividends?

CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.

What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?

CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.15.

How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?

CARsgen Therapeutics Holdings Ltd. has 577,973,140 shares outstanding.

What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?

CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.153 in its last earnings report, beating expectations of -HK$0.437. Following the earnings report the stock price went up 7.177%.

Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?

Currently, no hedge funds are holding shares in HK:2171

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CARsgen Therapeutics Holdings Ltd. Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

-42.46%

Trailing 12-Months

Asset Growth

-26.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CARsgen Therapeutics Holdings Ltd.

CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.